Klotho Cognitive Restoration Protocol (Research)
Elevate circulating KL1 (alpha-Klotho fragment) to restore synaptic plasticity and prefrontal GluN2B signaling in age-related cognitive decline. Amplified by BDNF upregulation (Semax) and neuroprotective synaptic enhancement (Dihexa).
Want a personalised protocol?
Our AI generator builds a protocol tailored to your profile and goals.
This protocol is an educational example only. It does not apply to your specific health situation. Medical supervision is required. Peptide therapy is not approved by regulatory bodies for many of the described indications.
Protocol Stack
KL1 (Klotho fragment)
PrimaryDose
Experimental β not established in humans
Frequency
1x every 2 weeks SC (research protocol)
Timing
Morning, fasted
Duration
6 injections, then 12-week assessment pause
Semax
SupportingDose
400β600 mcg
Frequency
Daily intranasal
Timing
Morning
Duration
4 weeks on / 2 weeks off
Dihexa
OptionalDose
5β10 mg
Frequency
3x/week SC or oral
Timing
Morning
Duration
4 weeks on / 4 weeks off
Monitoring Parameters
- βPlasma Klotho levels β baseline and every 4 weeks
- βMoCA score β baseline, week 6, week 12
- βComprehensive neuropsychological battery (MMSE, verbal memory, processing speed)
- βPhosphate and calcium panel (FGF23/Klotho axis effect on mineral metabolism)
- βRenal function (eGFR, creatinine) β monthly
- βBDNF plasma levels (optional) β baseline and week 12
- βBrain MRI (optional research endpoint) β baseline and month 6
Expected Outcomes
Weeks 2β4: Semax-driven BDNF elevation; early attention and focus improvement (detectable on Trail Making Test)
Weeks 6β8: KL1 cumulative effect on GluN2B expression β measurable improvement in episodic memory and working memory tasks
Week 12: MoCA reassessment β expected 2β4 point improvement in responders (based on primate analogy)
Month 6: Brain MRI may show preservation or partial reversal of cortical thinning in frontal regions (theoretical, research endpoint)
Contraindications
- βTIER 4 β KL1 has no approved human use. For research/educational purposes only.
- βChronic kidney disease stages 3β5 (Klotho-FGF23 axis is critically dysregulated in CKD)
- βHyperphosphatemia or hypercalcemia
- βActive neurodegenerative diagnosis (Alzheimer's, Parkinson's) β effect unknown, theoretical risk
- βPregnancy and breastfeeding
Clinical Notes
Klotho's role as an aging suppressor was discovered accidentally in 1997 when Klotho-knockout mice developed a premature aging syndrome. Since then, epidemiological data consistently show that higher circulating Klotho levels predict better cognition, lower cardiovascular risk, and longer lifespan in humans. The KL1 domain fragment (rather than full-length Klotho) is preferred because it can be produced recombinantly and appears to mediate the cognitive benefits independently of the FGF23 co-receptor function β reducing the risk of phosphate metabolism side effects. Semax was chosen as supporting because it directly upregulates BDNF and NGF β complementing KL1's synaptic plasticity mechanism through a distinct pathway. Dihexa (a potent HGF/Met signaling activator, reportedly 10,000,000x more potent than BDNF in synaptic facilitation assays) is added as optional for advanced research stacks where maximal synaptic enhancement is the goal.
Case Study
Clinical Practice Example
Female, 68, retired academic. MoCA 22/30 (mild cognitive impairment), plasma Klotho 420 pg/mL (below median for age), plasma BDNF 18 ng/mL (low). Normal renal function (eGFR 74), phosphate 0.98 mmol/L (normal). Enrolled in hypothetical KL1 research protocol: KL1 SC every 2 weeks (6 injections) + Semax 500 mcg daily intranasal + Dihexa 7.5 mg 3x/week SC. Week 6: plasma Klotho 680 pg/mL, BDNF 27 ng/mL. Week 12: MoCA 26/30 (+4), verbal memory improved from 5th to 28th percentile on standardized testing. Patient reported: 'I can follow conversations again and remember names.' Phosphate and calcium remained normal throughout. Note: Hypothetical educational case β no human trial data for KL1 fragment exists.